Sarepta Soars on FDA Submission for Duchenne Drug
This article is for subscribers only.
Sarepta Therapeutics Inc. shares soared in late trading after the biotech company announced plans to begin submitting data to U.S. regulators on a drug for the rare disorder Duchenne muscular dystrophy.
Sarepta will begin submitting a rolling new drug application this week for eteplirsen and should complete its submission by the middle of the year, the company said in a May 19 statement.